Feature | February 07, 2014

Transcatheter Pump May Aid Heart Failure Patients

Procyrion Aortix Ventricular Assist Device Hemodynamic Support Heart Failure
February 7, 2014 — Start-up company Procyrion Inc. is developing a catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure. The 6-mm diameter Aortix device is narrower than a pencil and is delivered via a catheter in a minimally invasive outpatient procedure lasting about 10 minutes.
 
Currently, long-term mechanical circulatory support (MCS) is limited to large ventricular assist devices (VADs). These devices are mainly used in patients with late stage heart failure (HF). Procyrion is developing a percutaneous intra-aortic micro-axial fluid entrainment pump called Aortix intended for long-term MCS in patients with earlier stage HF.
 
Aortix has been successfully tested with computer models, on the bench top in mock flow loops and in vivo in large animal HF studies. In three porcine experiments conducted last year, the pump was deployed in the thoracic aorta by standard cardiac catheterization techniques and was anchored with self-expanding struts. Acute cardiac dysfunction was induced by infusing esmolol continuously. Pump support increased cardiac output (+10.4 percent), stroke volume (+8.9 percent), and ejection fraction (+10.8 percent) while decreasing cardiac stroke work (-10.8 percent) and afterload (-22.7 percent). Pump support enhanced renal perfusion through sustained increases in both renal artery flow (+36.4 percent) and pressure (+73.6 percent).
 
In a porcine model of acute HF, the catheter-based intra-aortic fluid entrainment pump improved hemodynamics and renal perfusion. These results suggest the pump could improve HF outcomes and patients' quality of life by resting the heart, promoting reverse remodeling and augmenting end-organ perfusion. The renal perfusion may help disrupt the cardiorenal syndrome cycle and improve HF treatment.
 
The company received the Commercialization award by the Gulf Coast Regional Center of Innovation and Commercialization in February 2013 and received a total of $1.5 million in assistance from the Texas Emerging Technology Fund.  
 
 
For more information: www.procyrion.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD) | May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD) | April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD) | April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD) | March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD) | March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD) | March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init